EGFR and neoplasm: By realization of two bioactivity-enhancing principles in one molecule, i.e. hexa- or dodecavalent configuration of TRAIL and binding to EGFR-positive tumour cells, IgG-scTRAIL combines efficient cell death induction in tumour cells with targeted delivery.